SCHEMBL4153120

SCHEMBL4153120

CC(c1nc(=O)c(O)c2n1CCN(Cc1ccc(F)cc1)C2=O)N(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.43
KCNH2 Q12809 1/20 0.43
CYP2D6 P10635 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
TP53 P04637 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CLPP Q16740 2/20 0.37
RAB9A P51151 1/20 0.36
POLB P06746 3/20 0.36
ALDH1A1 P00352 1/20 0.36
SCD O00767 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
AKR1B1 P15121 1/20 0.35
NPC1 O15118 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4156706 0.86 KCNH2 (0.43) GRM2KCNH2CYP2D6HRH3TP53
SCHEMBL4144321 0.82 GRM2 (0.45) GRM2KCNH2CYP2D6HRH3TP53
SCHEMBL4153055 0.82 GRM2 (0.51) GRM2KCNH2CYP2D6HRH3TP53
SCHEMBL15862940 0.79 CLPP (0.43) GRM2KCNH2CYP2D6HRH3TP53
SCHEMBL4153119 0.79 KCNH2 (0.42) GRM2KCNH2CYP2D6HRH3TP53
SCHEMBL4153402 0.78 KCNH2 (0.45) GRM2KCNH2CYP2D6HRH3TP53
SCHEMBL5998353 0.78 KCNH2 (0.45) GRM2KCNH2CYP2D6HRH3TP53
SCHEMBL14260043 0.77 KCNH2 (0.47) GRM2KCNH2TP53MEN1KMT2A
SCHEMBL4161826 0.76 KCNH2 (0.45) GRM2KCNH2HRH3MEN1KMT2A
SCHEMBL19381753 0.76 GRM2 (0.39) GRM2KCNH2CYP2D6HRH3TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161639-A1 Hiv integrase inhibitors ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-07-12 US claimed
US-20090099168-A1 HIV Integrase inhibitors DONGHI MONICA 2009-04-16 US disclosed
US-20090099168-A1 HIV Integrase inhibitors DONGHI MONICA 2009-04-16 US disclosed
US-20090099168-A1 HIV Integrase inhibitors DONGHI MONICA 2009-04-16 US disclosed
US-20070161639-A1 Hiv integrase inhibitors ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-07-12 US disclosed
US-20070161639-A1 Hiv integrase inhibitors ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-07-12 US disclosed
US-20070161639-A1 Hiv integrase inhibitors ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161639-A1 Hiv integrase inhibitors DPYD, DUT, TYMP GRM2 3168/4885KCNH2 666/4885CYP2D6 296/4885
US-20090099168-A1 HIV Integrase inhibitors DPYD, DUT, QDPR GRM2 3764/4885KCNH2 722/4885CYP2D6 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.